Pedram Javanmard, MD
Endocrinology, Diabetes & Metabolism · Falls Church, VANPI 1033475413
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 258 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 41 manufacturers, the largest accounting for just 14.1% — the pattern of someone who eats at a lot of different presentations.
Across 258 payments — averaging $22.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$805
- Novo Nordisk$689
- Sanofi-aventis U.S. LLC$493
- Amneal Pharmaceuticals LLC$366
- Boehringer Ingelheim$295
- Corcept Therapeutics$277
- plus $3K from 35 others
What the payments were for
- Food & beverage$5,689100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 39 | $805 |
| Novo Nordisk | 39 | $689 |
| Sanofi-aventis U.S. LLC | 17 | $493 |
| Amneal Pharmaceuticals LLC | 16 | $366 |
| Boehringer Ingelheim | 13 | $295 |
| Corcept Therapeutics | 11 | $277 |
| Abbott | 9 | $252 |
| Xeris Pharmaceuticals, Inc. | 13 | $239 |
| Amgen(2 entities) | 9 | $171 |
| BETA Bionics, Inc. | 3 | $167 |
| Medtronic | 8 | $162 |
| Radius Health, Inc. | 6 | $149 |
| AstraZeneca(2 entities) | 7 | $148 |
| Insulet Corporation | 7 | $147 |
| Antares Pharma, Inc. | 6 | $131 |
| Mannkind Corporation | 5 | $123 |
| Bayer | 5 | $120 |
| Amryt Pharma Holdings Ltd | 5 | $108 |
| Recordati_rare_diseases_inc. | 4 | $81 |
| Ascendis Pharma Endocrinology Inc | 3 | $70 |
| Nevro Corp. | 2 | $68 |
| Amphastar Pharmaceuticals, Inc. | 4 | $67 |
| Ultragenyx Pharmaceutical Inc. | 3 | $56 |
| Novartis | 2 | $44 |
| Astellas Pharma US Inc | 2 | $42 |
| Dexcom, Inc. | 2 | $41 |
| AbbVie | 2 | $33 |
| Tandem Diabetes Care, Inc. | 2 | $32 |
| Neurocrine Biosciences, Inc. | 1 | $32 |
| Madrigal Pharmaceuticals | 1 | $32 |
| BD | 1 | $31 |
| Tolmar, Inc. | 2 | $30 |
| Boston Scientific | 1 | $28 |
| Embecta Corp. | 1 | $27 |
| Halozyme Inc | 1 | $25 |
| Amarin Pharma, Inc. | 1 | $23 |
| EUSA Pharma (US) LLC | 1 | $21 |
| Pfizer | 1 | $18 |
| IBSA Pharma Inc. | 1 | $17 |
| Currax Pharmaceuticals LLC | 1 | $17 |
| Clarus Therapeutics Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,689 in reported general payments places this provider in the 75th percentile of 223 endocrinology, diabetes & metabolism providers in Virginia.
See all endocrinology, diabetes & metabolism providers in Virginia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 124 | $190,691 |
| TrulicityDulaglutide | 65 | $112,887 |
| JardianceEmpagliflozin | 91 | $103,173 |
| MounjaroTirzepatide | 60 | $102,380 |
| JanuviaSitagliptin Phosphate | 34 | $36,382 |
| RybelsusSemaglutide | 12 | $29,804 |
| Tresiba Flextouch U-100Insulin Degludec | 21 | $21,612 |
| FarxigaDapagliflozin Propanediol | 17 | $20,926 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 36 | $18,842 |
| Tresiba Flextouch U-200Insulin Degludec | 11 | $16,613 |
| Humalog Kwikpen U-100Insulin Lispro | 35 | $12,068 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 50 | $7,890 |
| Novolog FlexpenInsulin Aspart | 31 | $6,054 |
| Admelog SolostarInsulin Lispro | 29 | $6,020 |
| SynthroidLevothyroxine Sodium | 41 | $4,463 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $689 | $220,495136 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $805 | $215,268125 claims |
| Boehringer IngelheimJardiance | $295 | $103,17391 claims |
| AstraZenecaFarxiga | $148 | $20,92617 claims |
| AbbVieSynthroid | $33 | $4,46341 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $366 | $1,448120 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 223 endocrinology, diabetes & metabolism providers in Virginia.
Other endocrinology, diabetes & metabolism in Falls Church
- Firoozeh ShahidiFalls Church$5K
- Farhad ZangenehSterling$1.2M
- James MulindaRoanoke$788K
- Jeffrey SicatGlen Allen$657K
- Dewey BaileyRoanoke$645K
- Domenica RubinoArlington$608K
- Samamtha HudsonMidlothian$372K
- Elias SirajNorfolk$316K
- Allen BurrisPowhatan$261K
- Samim EnayatFairfax$217K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.